About Pharvaris BV
Pharvaris (NASDAQ:PHVS) is a biopharmaceutical company focused on developing innovative therapies for rare diseases, with a particular emphasis on hereditary angioedema (HAE), a disorder characterized by recurrent swelling attacks. Their project pipeline includes novel, small-molecule bradykinin B2 receptor antagonists, designed to provide rapid and reliable relief for HAE sufferers. Pharvaris aims to advance the treatment landscape of HAE by harnessing cutting-edge technology and drug development strategies, striving to improve patient outcomes and quality of life. Their objectives are centered on pushing the boundaries of scientific research to deliver breakthrough solutions that address unmet medical needs within the rare disease community.
Snapshot
Operations
Produtos e/ou serviços de Pharvaris BV
- Development of oral small molecules for the treatment of hereditary angioedema, a rare genetic disorder causing severe swelling.
- Research into novel mechanisms of action for bradykinin B2 receptor antagonists to address acute and prophylactic care in angioedema conditions.
- Expansion of the portfolio to include therapies for additional bradykinin-mediated diseases, leveraging their expertise in angioedema.
- Collaboration with other pharmaceutical companies for the co-development of innovative treatments for rare diseases.
- Engagement in clinical trials to confirm the efficacy and safety of their lead compounds in treating target conditions.
- Investment in advanced drug delivery technologies to improve patient experience and outcomes in taking their medications.
equipe executiva do Pharvaris BV
- Mr. Berndt Axel Edvard Modig CPA, M.B.A.Co-Founder, CEO & Executive Director
- Mr. David W. Nassif J.D.CFO, Chief Legal Officer & Corporate Secretary
- Ms. Anna Nijdam M.Sc., R.A.Head of Strategic Finance & Principal Accounting Officer
- Dr. Stefan Abele Ph.D.Chief Technology Operations Officer
- Ms. Annick DeschoolmeesterChief Human Resources Officer
- Dr. Peng Lu M.D., Ph.D.Chief Medical Officer
- Dr. Anne A. Lesage Ph.D.Chief Early Development Officer
- Mr. Wim Souverijns Ph.D.Chief Commercial Officer
- Maryann CiminoDirector of Corporate Relations